Megalis 20 mg contains tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor. While it's commonly used to treat erectile dysfunction, it also plays a key role in improving blood flow in patients with pulmonary arterial hypertension (PAH). In PAH, the arteries in the lungs become narrowed or stiff, making it harder for the heart to pump blood through them. This leads to high blood pressure in the lungs and puts strain on the right side of the heart.
MEGALIS 20 MG helps by relaxing the smooth muscle cells in the walls of the pulmonary arteries. It inhibits the PDE5 enzyme, which breaks down cyclic guanosine monophosphate (cGMP)—a molecule that promotes blood vessel dilation. By preserving cGMP levels, tadalafil causes the blood vessels in the lungs to dilate, reducing pulmonary artery pressure and improving blood flow. This lowers the workload on the heart and increases oxygen delivery throughout the body.
Because of this mechanism, tadalafil (at specific doses) is approved in many countries for treating PAH under different brand names. Megalis 20 mg may have similar effects, but it should only be used for PAH under strict medical supervision due to dosage and safety considerations.
Add your comment